INSIDE INFORMATION: NANOFORM SELECTS GLOBAL CDMO PARTNER FOR GMP MANUFACTURING OF ULTRA-HIGH-CONCENTRATION BIOLOGICS

Nanoform Finland Plc | Inside Information | November 17, 2026 at 08:10:00 EET

Helsinki, Finland – Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it has signed an agreement with a CDMO partner for implementation of Nanoform's biologics technology at one of the Partner's European facilities for aseptic manufacturing and fill and finish of biological products.

Headquartered in Europe, the CDMO partner is a global leader in aseptic manufacturing of biologics and can support projects ranging from early clinical to commercial manufacturing. The agreement represents an important step in advancing Nanoform's biologics technology towards clinical application. The parties will establish a dedicated production line for Nanoform's biologics technology within the CDMO's existing aseptic manufacturing facility in Germany. The facility has existing capabilities for the manufacture of injectable biologics under Good Manufacturing Practice (GMP) standards, including aseptic processing and fill-and-finish.

For Nanoform's customers, the collaboration provides an accelerated pathway from formulation and preclinical development at Nanoform through to GMP manufacture and supply of material for clinical trials and later commercial manufacturing. Combining Nanoform's biologics technology and development capabilities with an established CDMO's aseptic infrastructure, quality systems and manufacturing expertise accelerates the transition into clinical development.

Nanoform and the CDMO partner target GMP readiness during the second half of 2027 in order to support a planned first customer clinical trial of a subcutaneous ultra-high concentration suspension biologic product enabled by nanoforming. The agreement does not have an immediate material financial effect on Nanoform.

Edward Hæggström, Chief Executive Officer of Nanoform, commented:

"We are pleased to have identified an excellent partner to enable us to accelerate our customers' entry to clinic with subcutaneous ultra-high concentration suspension products enabled by nanoforming. We look forward to the implementation work at the partner's site during the coming months. Both we and our customers are impressed by the expertise and speed by which this cooperation has started."

Christian Jones, Chief Commercial Officer of Nanoform, commented:

"Enabling clinical supply is fundamental for our customers and partners also on the biologics side. The partnership announced today will provide an accelerated pathway to clinical supply of GMP material with a CDMO partner that is a global leader in aseptic manufacturing and has a strong network to support our joint customers. Nanoform believes subcutaneous delivery will become the dominant standard for new and marketed biologics. Nanoform's suspension formulations enable high drug concentrations with particle properties that are critical for suspension performance."

For further information, please contact:

Christian Jones, CCO

christian.jones@nanoform.com

+44 (0)7804 474771

Henri von Haartman, DIR

hvh@nanoform.com

+46 (0)7686 650 11

This information is inside information that Nanoform is obliged to disclose pursuant to the EU Market Abuse Regulation (EU) No 596/2014. The information was submitted for publication through the agency of the contact person set out above, on November 17th, 2026, at 08.10 EET / 07.10 CET.

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform' s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, **certifiedadviser@dnbcarnegie.se**. For more information, please visit **www.nanoform.com**.

Nanoform forward-looking statements

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", "believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2025 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or

circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Attachments

Inside information: Nanoform Selects Global CDMO Partner for GMP Manufacturing of Ultra-High-Concentration Biologics